Status:

UNKNOWN

Supplementation of Brown Seaweed on Insulin Resistance of NAFLD Patients With Pre- or Type 2-Diabetes

Lead Sponsor:

Taipei Medical University WanFang Hospital

Collaborating Sponsors:

Hi-Q Marine Biotech International, Ltd.

Conditions:

Type II Diabetes

Eligibility:

All Genders

20-75 years

Phase:

NA

Brief Summary

Investigators research team conducted a previous human clinical trial of brown algae and conducted liver and metabolic indicators of brown algae to improve nonalcoholic fatty liver disease, and found ...

Detailed Description

Brown seaweeds rich in flavonoids and bioactive polysaccharides have been shown the potential effects on suppressing fat accumulation, oxidative stress and inflammation in liver. The refined seaweed c...

Eligibility Criteria

Inclusion

  • Between the ages of 20 and 75 years old, biochemical test data and abdominal ultrasound screening were selected according to the following conditions.
  • Prediabetes: AC at 101 to 125 and HbA1c at 5.8 to 6.4 and abdominal ultrasound confirmed fatty liver.
  • Type 2 Diabetes: Abdominal ultrasound confirms the presence of fatty liver; Hypoglycemic agent HbA1c controls 8% (but does not contain Pioglitazone or injection of Liraglutide), or patient HbA1c is controlled below 9% but does not want to increase drug Dosage or add other hypoglycemic agents.

Exclusion

  • Severe renal insufficiency (diabetic or eGFR less than 30 mL/min/1.73 m2), severe heart failure (NYHA function classification III or IV), etc.
  • Allergies to seafood and seaweed ingredients.
  • Cannot or refuse to sign test consent.
  • Inject insulin or Liraglutide or take Pioglitazone.
  • Type 1 diabetes patients.
  • People who drink alcohol and take weight-related drugs and health products.
  • There are blood transfusion recipients within three months.

Key Trial Info

Start Date :

December 10 2018

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

February 28 2021

Estimated Enrollment :

106 Patients enrolled

Trial Details

Trial ID

NCT04715776

Start Date

December 10 2018

End Date

February 28 2021

Last Update

January 20 2021

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Wanfang Hospital

Taipei, Wenshan District, Taiwan, 116